-
Home-made cell therapy equipment ushered in a golden age with broad development space
Time of Update: 2021-09-30
On September 7th, a total of 23 institutions investigated Tailin Biology, focusing on the research and development history of key cell therapy equipment, the market space of cell therapy equipment, and the main technical barriers of the company's products .
-
This targeted therapy has huge potential, and domestic and foreign pharmaceutical companies are competing for deployment
Time of Update: 2021-09-30
Recently, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Novo Nordisk has declared an oral preparation NNC0385-0434 targeting PCSK9, which has obtained the implied license for clinical trials and is planned to be developed for use in: Treatment for lowering low-density lipoprotein cholesterol (LDL-C) in adult patients with zygotic familial hypercholesterolemia, confirmed cardiovascular disease, or high cardiovascular risk, used alone or in combination with statins .
-
KN046 registered clinical IND approved for non-small cell lung cancer that has progressed after PD-(L)1 treatment
Time of Update: 2021-09-30
HK) announced that the company's self-developed recombinant humanized PD-L1/CTLA-4 bispecific antibody KN046 and A registered clinical IND was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, agreeing to carry out a multi-center, randomized, open, positive-controlled phase II/III clinical study (study number: ENREACH-LUNG-02/KN046) -302), to evaluate the effectiveness, safety and tolerability of KN046 combined with lenvatinib versus docetaxel in patients with advanced non-small cell lung cancer who have previously received anti-PD-(L)1 treatment .
-
The Sci-tech Innovation Board has tightened supervision, and another pharmaceutical company's IPO has been denied
Time of Update: 2021-09-30
Following the rejection of the Haihe Pharmaceutical Science and Technology Innovation Board IPO on September 17, another pharmaceutical company was rejected recently . On September 22, public inform
-
The medical market has a bright future, and Internet companies are accelerating their deployment
Time of Update: 2021-09-30
Specifically, on September 9, 2021, ByteDance invested in two companies through its wholly-owned subsidiary Xiaohe Health, namely Beijing Meizhongyihe Medical Management (Group) Co.
Industry analysts believe that it is obvious from the above that Bytedance's layout in the medical and health field is deepening from offline medical to asset-heavy medical services .
-
Experts remind: Periodontitis is the primary factor leading to tooth loss
Time of Update: 2021-09-30
Liu Yuzhi said that special attention should be paid to several stages in the prevention, treatment, and control of periodontal disease .
Liu Yuzhi said that special attention should be paid to several stages in the prevention, treatment, and control of periodontal disease .
-
In order to improve the quality of medicines, pharmaceutical companies will continue to increase their investment in pharmaceutical equipment
Time of Update: 2021-09-30
At the same time, with the advancement of more pharmaceutical equipment intelligent manufacturing projects, it will also help improve the overall intelligent level of China's pharmaceutical equipment, promote the intelligent transformation and upgrading of the pharmaceutical industry, and provide better guarantees for the quality and safety of pharmaceutical production .
-
In the second half of the year, the specialty API sector may usher in an inflection point of growth
Time of Update: 2021-09-30
. Second, pay attention to the integration opportunities of API preparations: the bottom interval is established, the inflection point is approaching, and the double-click will always come: Under multiple disturbance factors such as exchange rate, price, epidemic situation, and emergencies, API preparation integration companies have experienced more than half a year of adjustments and performance The stock price of Hehe is already in the bottom range, and the short-term negatives are expected to be exhausted.
-
CDK4/6 smokes again!
Time of Update: 2021-09-30
The Harmonia study is the first prospective phase III trial to recruit patients with specific tumor molecular subtypes at the RNA level, and it is also the first clinical trial to conduct a head-to-head comparison of CDK4/6 inhibitors in patients with HR+/HER2-advanced breast cancer .
-
Wanchun Pharmaceutical Announces Phase III Data of Pranabrin
Time of Update: 2021-09-30
Article source: Medical Rubik's Cube InfoOn September 21st, Wanchun Medicine issued an oral report at the ESMO2021 conference on the international multi-center of the second/third-line treatment of pranabulin combined with docetaxel versus docetaxel for the second/third-line treatment of EGFR wild-type non-small cell lung cancer patients Detailed results of the Phase III study (DUBLIN-3) .
-
Many pharmaceutical companies now have personnel changes! Including chairman, deputy general manager and other positions
Time of Update: 2021-09-30
Kangmei Pharmaceutical: Supervisor resigns On September 17, Kangmei Pharmaceutical issued an announcement stating that due to personal reasons, Zhong Shaozhu resigned as employee supervisor of the company .
Lawrence Allan Hill applied to resign from the position of Deputy General Manager of the company due to personal reasons .
-
In the future, the medical device sector is still expected to maintain a high boom
Time of Update: 2021-09-30
On the whole, the industry generally believes that the medical device sector is expected to remain in the future.
With the strengthening of new infrastructure at home and abroad, the medical device sector is still expected to maintain a high boom .
-
Cinda Biotech announced that the National Medical Products Administration has accepted the application for new indications for the treatment of first-line esophageal squamous cell carcinoma patients with daboshu (sintilimab injection) combined with chemotherapy
Time of Update: 2021-09-30
San Francisco, USA and Suzhou, China September 23, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales f
-
Another pharmaceutical company has entered the battle for over 15 billion yuan in the contrast agent market!
Time of Update: 2021-09-30
In addition, in February of this year, Chengdu Better Pharmaceuticals also issued an announcement stating that its application for imitation listing of Category 4 iopromide injection was accepted, and it became the company's first contrast agent to apply for listing .
-
The time for the fifth batch of national procurement bids in 14 provinces and cities has been confirmed!
Time of Update: 2021-09-30
Another province has confirmed the bidding time! Tonight continue to share the implementation of the fifth batch of national procurement . Following the 13 provinces and cities shared before, today H
-
The era of strong medical equipment supervision has come, and medical equipment personnel will face the normalization of unannounced inspections
Time of Update: 2021-09-30
The notice pointed out that for the 45 general defects found in the inspection, the Sichuan Provincial Drug Administration has ordered relevant companies to rectify within a time limit, and required companies to implement the main responsibility for quality and safety, analyze and find reasons, evaluate safety risks, and for those that may cause safety hazards, Recall related products in accordance with the "Medical Device Recall Management Measures" .
-
Centralized procurement of proprietary Chinese medicines has been launched everywhere, and Chinese medicine companies need to accelerate their transformation
Time of Update: 2021-09-30
In addition, in August this year, the National Medical Insurance Administration made it clear that it would start with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of proprietary Chinese medicines and formula particles, and further accelerated the procurement of proprietary Chinese medicines .
-
Hutchison Whampoa third-generation BTK inhibitor approved for clinical treatment of B-cell non-Hodgkin's lymphoma
Time of Update: 2021-09-30
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn September 23, the CDE official website showed that the Hutchison Whampoa HMPL-760 capsule clinical trial application was approved by the Food and Drug Administration for the treatment of B-cell non-Hodgkin's lymphoma .
-
The commercial production of biopharmaceuticals is facing many problems, how to solve them
Time of Update: 2021-09-30
Especially in the current stage of accelerated commercial production of biopharmaceuticals, the industry has generally believed that high-end biopharmaceutical equipment will become an indispensable pharmaceutical aid .
-
The results of the global phase 2/3 clinical trial of the clover new crown candidate vaccine show that the protective effect of the Delta variant strain is 79%
Time of Update: 2021-09-30
A total of more than 30,000 adult and elderly subjects were enrolled in the "SPECTRA" Phase 2/3 clinical trials on four continents around the world. In the analysis of protection effectiveness, 100%
